Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population

References

• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–38
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–24
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–9
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16:338–46
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189–98
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018–24
   PubMed Web of Science ®Google Scholar
• Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause 2013;20:138–45
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013;121:959–68
   PubMed Web of Science ®Google Scholar
• Blumel JE, Chedraui P, Baron G, et al. Menopausal symptoms appear before the menopause and persist 5 years beyond: a detailed analysis of a multinational study. Climacteric 2012;15:542–51
   PubMed Web of Science ®Google Scholar
• Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. European Medicines Agency 2005 October 13; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003348.pdf
   Google Scholar
• Chedraui P, Blumel JE, Baron G, et al. Impaired quality of life among middle aged women: a multicentre Latin American study. Maturitas 2008;61:323–9
   PubMed Web of Science ®Google Scholar
• Leon-Leon P. Assessment of quality of life in the menopause in Ecuador and Latin America [abstract 72]. Maturitas 2009;63(Suppl 1):S20
   Google Scholar
• Tserotas K, Hernandez L, Morera F, Pineda R, Chedraui P. Treatment for the menopause in Central America: use, knowledge, perceptions and attitudes among urban living middle-aged women. Gynecol Endocrinol 2011;27:504–11
   PubMed Web of Science ®Google Scholar
• Bassol S, Carranza-Lira S, Celis-Gonzalez C, et al. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women. Maturitas 2005;50:189–95
   PubMed Web of Science ®Google Scholar
• Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol 2010;26:333–7
   PubMed Web of Science ®Google Scholar
• Carmignani LO, Pedro AO, Costa-Paiva LH, Pinto-Neto AM. The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas 2010;67:262–9
   PubMed Web of Science ®Google Scholar
• Aedo S, Cavada G, Campodonico I, Porcile A, Irribarra C. Sertraline improves the somatic and psychological symptoms of the climacteric syndrome. Climacteric 2011;14:590–5
   PubMed Web of Science ®Google Scholar
• Morais-Socorro M, Cavalcanti MA, Martins R, et al. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial. Gynecol Endocrinol 2012;28:483–7
   PubMed Web of Science ®Google Scholar
• Blumel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011;18:778–85
   PubMed Web of Science ®Google Scholar
• Blumel JE, Chedraui P, Baron G, et al. Sexual dysfunction in middle-aged women: a multicenter Latin American study using the Female Sexual Function Index. Menopause 2009;16:1139–48
   PubMed Web of Science ®Google Scholar
• Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507–13
   PubMed Web of Science ®Google Scholar
• Hou N, Hong S, Wang W, et al. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst 2013;105:1365–72
   PubMedGoogle Scholar
• Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005;20:185–94
   PubMed Web of Science ®Google Scholar
• Bauer RL, Deyo RA. Low risk of vertebral fracture in Mexican American women. Arch Intern Med 1987;147:1437–9
   PubMed Web of Science ®Google Scholar
• Bauer RL. Ethnic differences in hip fracture: a reduced incidence in Mexican Americans. Am J Epidemiol 1988;127:145–9
   PubMed Web of Science ®Google Scholar
• Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009;20:275–82
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002;17:1237–44
   PubMed Web of Science ®Google Scholar
• Zanchetta J, Campusano C, Muzzi B, et al. The Latin America Regional Audit: Epidemiology, costs & burden of osteoporosis in 2012. Nyon, Switzerland: International Osteoporosis Foundation, 2012
   Google Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203–4
   PubMed Web of Science ®Google Scholar
• Maia H Jr, Albernaz MA, Baracat EC, et al. Latin American position on the current status of hormone therapy during the menopausal transition and thereafter. Maturitas 2006;55:5–13
   PubMed Web of Science ®Google Scholar
• Blumel JE, Chedraui P, Baron G, et al. A multicentric study regarding the use of hormone therapy during female mid-age (REDLINC VI). Climacteric 2014;17:433–41
   PubMed Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol 2012;120:595–603
   PubMed Web of Science ®Google Scholar
• Ameye L, Antoine C, Paesmans M, de Azambuja E, Rozenberg S. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas 2014;79:287–91
   PubMed Web of Science ®Google Scholar
• Miranda JJ, Herrera VM, Chirinos JA, et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One 2013;8:e54056
   PubMed Web of Science ®Google Scholar
• Royer M, Castelo-Branco C, Blumel JE, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007;10:164–70
   PubMed Web of Science ®Google Scholar
• Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD: National Center for Health Statistics, 2011
   Google Scholar
• Castelo-Branco C, Blumel JE, Chedraui P, et al. Age at menopause in Latin America. Menopause 2006;13:706–12
   PubMed Web of Science ®Google Scholar
• Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010;13:419–28
   PubMed Web of Science ®Google Scholar
• Velez MP, Alvarado B, Lord C, Zunzunegui MV. Life course socioeconomic adversity and age at natural menopause in women from Latin America and the Caribbean. Menopause 2010;17:552–9
   PubMed Web of Science ®Google Scholar
• Ojeda E, Monterrosa A, Blumel JE, Escobar-Lopez J, Chedraui P. Severe menopausal symptoms in mid-aged Latin American women can be related to their indigenous ethnic component. Climacteric 2011;14:157–63
   PubMed Web of Science ®Google Scholar